Which medications are used for CRPS?
Doctors treat complex regional pain syndrome (CRPS) with nerve pain medications such as gabapentin and tricyclic antidepressants, short courses of steroids, bisphosphonates, topical creams and sometimes opioids. All are used off label, meaning they are approved for other conditions. A 2023 Cochrane overview found no high-certainty evidence for any of them.

Is any medication approved by the FDA for CRPS?
No medication is approved by the Food and Drug Administration specifically for complex regional pain syndrome, according to a 2024 systematic review by Zhu and colleagues, which states, "At present, there is no FDA-approved pharmacological treatment for patients with CRPS." The National Institute of Neurological Disorders and Stroke says the medicines "are used 'off label' to treat CRPS. This means they are approved for other conditions."
The same is true in the United Kingdom. The Royal College of Physicians' 2018 guideline states, "No drugs are licensed to treat CRPS in the UK." The 2022 practical guidelines in Pain Medicine name approvals for other conditions only, such as carbamazepine for trigeminal neuralgia and the lidocaine 5 percent patch for nerve pain after shingles.
Which medications do doctors usually start with for CRPS?
Guidelines start with simple pain medicines and move to nerve pain medicines if CRPS pain continues. The Royal College of Physicians' 2018 guideline has the treating team begin simple analgesics such as paracetamol, anti-inflammatory drugs or codeine. The guideline notes that these drugs "do not necessarily affect the specific pain of CRPS but may reduce ongoing trauma-related pains and assist in the process of mobilisation."
The next step in the Royal College of Physicians' guideline is a drug with proven effect in neuropathic pain, meaning pain from nerves. The guideline names the tricyclic antidepressants nortriptyline, imipramine and amitriptyline and the anticonvulsants gabapentin and pregabalin. The guideline adds that a patient who needs these drugs or strong opioids should be considered for urgent referral to a pain consultant.
What does the evidence show for each CRPS medication?
Each class of CRPS medication has limited trial evidence. The table names the main study for the classes most often prescribed.
| Medication class | Main study in CRPS | Evidence strength |
|---|---|---|
| Gabapentin for CRPS | van de Vusse, 2004: crossover trial in CRPS type I reported "a mild effect on pain" | Low |
| Tricyclic antidepressants for CRPS | No randomized trial in adults with CRPS (Cochrane overview, 2023) | Borrowed from other nerve pain |
| Corticosteroids for CRPS | Christensen, 1982: all 13 patients on prednisone improved more than 75 percent, against 2 of 10 on placebo | Low; early disease |
| Bisphosphonates for CRPS | Ferraro, 2026: 11 trials, 754 participants; pain 10.0 points lower on a 0 to 100 scale at 4 weeks to 3 months | Low certainty |
| Opioids for CRPS | One trial of controlled-release morphine: no difference from placebo after 8 days | No supporting trial |
| Topical DMSO 50 percent for CRPS | Zuurmond, 1996: better score improvement than placebo cream in 32 patients | Low |
| Low-dose naltrexone for CRPS | Chopra, 2013: report of two patients | Very low |
Do gabapentin and pregabalin work for CRPS?
Gabapentin showed a mild effect in its one CRPS trial, and pregabalin has not been tested in CRPS. The 2004 crossover trial by van de Vusse and colleagues in CRPS type I reported that gabapentin had "a mild effect on pain" and reduced sensory deficit, with no significant effect when both treatment periods were combined. The 2022 practical guidelines note that the trial used a dose below the maximum, 1,800 mg a day.
The 2022 practical guidelines state, "There are no clinical trial data evaluating pregabalin for CRPS." Large trials support gabapentin in other nerve pain conditions, such as nerve pain after shingles and diabetic neuropathy, and the guidelines describe pregabalin as a closely related compound.
Are antidepressants used to treat CRPS pain?
Tricyclic antidepressants are widely used for CRPS pain without a CRPS trial behind them. The 2023 Cochrane overview reported, "We did not identify any RCT evidence for routinely used pharmacological interventions for CRPS such as tricyclic antidepressants or opioids." The 2022 practical guidelines rely on meta-analyses of trials in other nerve pain, and note that these drugs also treat insomnia, anxiety and depression.
The newer antidepressants called SNRIs, which include duloxetine and venlafaxine, are approved for several chronic pain conditions. The 2022 practical guidelines state that SNRIs "have not been trialed for CRPS." The guidelines call for comparative data on tricyclics and SNRIs in CRPS.
Do steroids help early CRPS?
Two small trials reported improvement with oral steroids in early or post-stroke CRPS. In Christensen's 1982 trial of 23 patients, all 13 who took prednisone 10 mg three times a day for up to 12 weeks improved by more than 75 percent, compared with 2 of 10 on placebo. In Kalita's 2006 trial of 60 patients with CRPS after stroke, 83.3 percent improved on prednisolone and 16.7 percent on the anti-inflammatory piroxicam.
The 2022 practical guidelines limit the role of steroids in CRPS. The guidelines state that "a short course of steroids may be indicated in early CRPS with prominent inflammation, but longer courses are unproven," and that in persistent CRPS steroids "are rarely effective."
What do studies and guidelines say about opioids for CRPS?
Opioids have no supporting trial in CRPS, and guidelines discourage long-term use. The 2022 practical guidelines report that only one randomized trial has tested an opioid in CRPS, controlled-release morphine, "reporting no difference in pain reduction when compared to placebo after 8 days' use." The guidelines add that the trial would not meet current quality standards, so the question of short-term benefit remains open.
The Royal College of Physicians' 2018 guideline states that "long-term opioid treatment is rarely appropriate" in CRPS. The National Institute of Neurological Disorders and Stroke says long-term opioid use "can sometimes make pain harder to control." The 2022 practical guidelines describe lower doses as a reasonable second or third line option and say doses should not be escalated freely.
Are bisphosphonates a medication for CRPS?
Bisphosphonates, which are bone drugs, have more placebo-controlled CRPS trials than any other medication class. In Varenna's 2013 trial of 82 patients with acute CRPS type I, pain fell by 46.5 mm on a 100 mm scale with four infusions of neridronate and by 22.6 mm with placebo. A 2026 meta-analysis by Ferraro and colleagues pooled 11 trials and found a smaller, short-term effect with low certainty.
The 2026 meta-analysis notes that neridronate and clodronate are not approved formulations in the United States. The Royal College of Physicians' 2018 guideline says a single 60 mg intravenous dose of pamidronate "should be considered for suitable patients with CRPS less than 6 months in duration." Details are in bisphosphonates and neridronate.
Which creams and patches are used for CRPS?
Topical treatments for CRPS include dimethyl sulfoxide (DMSO) cream, lidocaine patches and capsaicin. In Zuurmond's 1996 trial of 32 patients with acute CRPS, DMSO 50 percent cream improved a clinical score more than placebo cream over two months. A 2003 trial by Perez and colleagues in 146 patients found DMSO cream and oral N-acetylcysteine "generally equally effective." The 2023 Cochrane overview rated the DMSO evidence low certainty.
The 2022 practical guidelines say the lidocaine 5 percent patch "may have efficacy in some local or focal CRPS phenomena such as allodynia," at level 4 evidence. Allodynia is pain from light touch. The same guidelines describe capsaicin as intolerably painful and unacceptable to most patients with CRPS.
What is known about low-dose naltrexone for CRPS?
Low-dose naltrexone for CRPS rests on case reports. Chopra and Cooper described two patients in 2013 whose prominent CRPS symptoms, including dystonic spasms, remitted after low-dose naltrexone was added to other treatment. A 2021 systematic review by Soin and colleagues found that most published studies concerned other chronic pain conditions and concluded that "there is a need for additional prospective and interventional studies" of low-dose naltrexone in CRPS. The 2022 practical guidelines noted that a trial was recruiting.
Which medications failed in CRPS trials?
Several medications did not outperform placebo in randomized CRPS trials. Low-dose intravenous immunoglobulin was "not effective in relieving pain" in Goebel's 2017 trial of 108 patients with CRPS of one to five years. Intravenous mannitol was "not more effective than placebo" in a 2008 trial of 41 patients by Perez and colleagues. The 2022 practical guidelines report that infliximab was ineffective in a preliminary trial and that lenalidomide was not effective in a large one.
The Royal College of Physicians' 2018 guideline says low-dose immunoglobulin and lenalidomide "should not be offered as there is definite evidence for a lack of effect."
How do guidelines say CRPS medications should be reviewed?
Guidelines call for agreed goals and regular review of CRPS medication. The 2022 practical guidelines say outcomes should be agreed with the patient before a drug is started, for example a pain reduction of two points on a 0 to 10 scale, and that the drug should be reconsidered if the target is not met. The guidelines also state that most patients develop tolerance to pain drugs over time while side effects often continue.
The Royal College of Physicians' 2018 guideline adds that where nerve pain drugs are not sufficiently effective, "drug reduction or drug cessation may improve the balance between effects and side effects." Any change to a CRPS medication is a decision for the prescribing doctor.
Common questions
Sources
Every source below was opened and read for this page. The date is when it was last checked.
- Complex Regional Pain SyndromeGovernment agency · National Institute of Neurological Disorders and Stroke · checked
- Complex Regional Pain Syndrome: Practical Diagnostic and Treatment Guidelines, 5th EditionClinical guideline · Pain Medicine (Harden et al.), 2022 · checked
- Complex regional pain syndrome in adults: UK guidelines for diagnosis, referral and management in primary and secondary care, 2nd editionClinical guideline · Royal College of Physicians, 2018 · checked
- Interventions for treating pain and disability in adults with complex regional pain syndrome: an overview of systematic reviewsStudy · Cochrane Database of Systematic Reviews (Ferraro et al.), 2023 · checked
- Efficacy and Safety of Pharmacological Treatment in Patients with Complex Regional Pain Syndrome: A Systematic Review and Meta-AnalysisStudy · Pharmaceuticals (Zhu et al.), 2024 · checked
- Randomised controlled trial of gabapentin in Complex Regional Pain Syndrome type 1Study · BMC Neurology (van de Vusse et al.), 2004 · checked
- The reflex dystrophy syndrome response to treatment with systemic corticosteroidsStudy · Acta Chirurgica Scandinavica (Christensen et al.), 1982 · checked
- Comparison of prednisolone with piroxicam in complex regional pain syndrome following stroke: a randomized controlled trialStudy · QJM (Kalita et al.), 2006 · checked
- Treatment of complex regional pain syndrome type I with neridronate: a randomized, double-blind, placebo-controlled studyStudy · Rheumatology (Varenna et al.), 2013 · checked
- Efficacy and Safety of Bisphosphonates for Complex Regional Pain Syndrome: A Systematic Review and Meta-analysisStudy · Annals of Internal Medicine (Ferraro et al.), 2026 · checked
- Treatment of acute reflex sympathetic dystrophy with DMSO 50% in a fatty creamStudy · Acta Anaesthesiologica Scandinavica (Zuurmond et al.), 1996 · checked
- The treatment of complex regional pain syndrome type I with free radical scavengers: a randomized controlled studyStudy · Pain (Perez et al.), 2003 · checked
- Treatment of Complex Regional Pain Syndrome (CRPS) using low dose naltrexone (LDN)Study · Journal of Neuroimmune Pharmacology (Chopra and Cooper), 2013 · checked
- Low-Dose Naltrexone Use for Patients with Chronic Regional Pain Syndrome: A Systematic Literature ReviewStudy · Pain Physician (Soin et al.), 2021 · checked
- Low-Dose Intravenous Immunoglobulin Treatment for Long-Standing Complex Regional Pain Syndrome: A Randomized TrialStudy · Annals of Internal Medicine (Goebel et al.), 2017 · checked
- Treatment of patients with complex regional pain syndrome type I with mannitol: a prospective, randomized, placebo-controlled, double-blinded studyStudy · The Journal of Pain (Perez et al.), 2008 · checked
- Rational pain management in complex regional pain syndrome 1 (CRPS 1): a network meta-analysisStudy · Pain Medicine (Wertli et al.), 2014 · checked
- Can vitamin C prevent complex regional pain syndrome in patients with wrist fractures? A randomized, controlled, multicenter dose-response studyStudy · The Journal of Bone and Joint Surgery, American Volume (Zollinger et al.), 2007 · checked
- The influence of vitamin C on the outcome of distal radial fractures: a double-blind, randomized controlled trialStudy · The Journal of Bone and Joint Surgery, American Volume (Ekrol et al.), 2014 · checked

CRPS treatment
Preventing CRPS after a fracture
CRPS symptom diary
CRPS clinical trial finder